Evidence of Liver Transplantation Clinical Trial
Official title:
Changes of Macrophage Migration Inhibitory Factor and Thyroid Hormones During Liver Transplantation. Association With Graft Dysfunction
Collecting blood, graft liver effluent and urine samples from patients undergoing orthotopic liver transplantation.
Aims are to measure Macrophage Migration Inhibitory Factor, Macrophage Migration Inhibitory Factor II and its' soluble receptor CD74 in serum, liver graft effluent and urine in and evaluate MIF's role in hepatic ischemia/reperfusion injury, postoperative graft function and kidney function. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02239991 -
Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant
|
N/A | |
Recruiting |
NCT03013634 -
Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation
|
N/A | |
Active, not recruiting |
NCT02579408 -
Quantifying Steatosis in Liver Transplant Donors
|
||
Completed |
NCT02008097 -
Clinical Benefits of B-Flow Ultrasound
|
N/A | |
Completed |
NCT04763096 -
Evaluate the Efficacy and Safety of the ADVAGRAF®
|
Phase 4 | |
Recruiting |
NCT01607788 -
Prospective Liver Tumor (ProLiT) Database
|
N/A | |
Recruiting |
NCT01766518 -
The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)
|
Phase 4 | |
Not yet recruiting |
NCT01860716 -
Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant.
|
Phase 3 | |
Completed |
NCT01022476 -
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
|
Phase 1/Phase 2 | |
Completed |
NCT01546064 -
Study to Establish Whether the Use of T-Tube in Bile Duct Anastomosis in Liver Transplantation Decreases Morbidity
|
N/A | |
Completed |
NCT02263703 -
Immunogenicity of HPV Vaccine in Immunosuppressed Children
|
Phase 3 | |
Terminated |
NCT00473824 -
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
|
Phase 2 | |
Terminated |
NCT00151632 -
Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT02350218 -
Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)
|
Phase 2 | |
Completed |
NCT02608606 -
Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors
|
N/A | |
Recruiting |
NCT02451046 -
Usefulness of Alpha-GST in Liver Transplantation
|
N/A | |
Completed |
NCT00177931 -
Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit
|
N/A | |
Completed |
NCT01147380 -
Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
|
Phase 1 | |
Terminated |
NCT00694408 -
A Pilot Trial of Pediatric Liver Transplantation Without Steroids
|
Phase 3 | |
Terminated |
NCT00375895 -
Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation
|
Phase 3 |